Centralised Adult Flu Procurement

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-04b1c0-2026-04-27T10:41:25+01:00",
    "date": "2026-04-27T10:41:25+01:00",
    "ocid": "ocds-h6vhtk-04b1c0",
    "initiationType": "tender",
    "tender": {
        "id": "C310432",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Centralised Adult Flu Procurement",
        "status": "planned",
        "classification": {
            "scheme": "CPV",
            "id": "33651600",
            "description": "Vaccines"
        },
        "mainProcurementCategory": "goods",
        "description": "Central Adult Flu Vaccine Procurement and Distribution Project Update To Industry.",
        "lots": [
            {
                "id": "1",
                "description": "UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:<br/>* Gain a better understanding of the 'as-is' adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers <br/>* Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration include<br/>o Procuring Adult Flu Vaccines using a Centralised Framework Contract<br/>o UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methods<br/>o UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution <br/>o Maintaining the status quo<br/><br/>* Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.<br/>* Have an open dialogue with the market to ensure a full understanding of the future landscape.<br/>The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.<br/><br/>Who would we like to hear from?<br/>We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.<br/><br/>How to participate?<br/>The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Sunday 17th November 2024.",
                "status": "planned"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "communication": {
            "futureNoticeDate": "2024-10-28T00:00:00Z",
            "atypicalToolUrl": "https://health-family.force.com/s/Welcome"
        },
        "coveredBy": [
            "GPA"
        ],
        "amendments": [
            {
                "id": "1",
                "unstructuredChanges": [
                    {
                        "oldValue": {
                            "text": "UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:* Gain a better understanding of the 'as-is' adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers * Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo* Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.* Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Sunday 17th November 2024."
                        },
                        "newValue": {
                            "text": "UKHSA, as the potential Contracting Authority, are leading the pre-market engagement activity with the purpose to:* Gain a better understanding of the 'as-is' adult NHS flu programme from the perspective of vaccine manufacturers and wholesalers * Understand what impact centralising the procurement and/or supply of adult flu vaccine would potentially have on the market including current capability and capacity; options under consideration includeo Procuring Adult Flu Vaccines using a Centralised Framework Contracto UKHSA Procuring Adult Flu Vaccines and maintaining existing supply and distribution methodso UKHSA Procuring Adult Flu Vaccines and ingesting supply centrally for distribution o Maintaining the status quo* Explore any potential barriers, opportunities, benefits or risks there may be with a central procurement and/or supply approach.* Have an open dialogue with the market to ensure a full understanding of the future landscape.The market engagement will take the form of a questionnaire available via our e-procurement system, which you will be asked to complete and return. Once returned, you may be invited for a 1:1 meeting with the project team to discuss your answers and provide clarification. It is anticipated that these meetings will take place during November/December 2024.Who would we like to hear from?We are keen to engage with those suppliers who already have a licenced adult flu vaccine and/or have experience of the UK adult flu market, who have an adult flu vaccine in development, or who may have an adult flu vaccine in their future product development pipeline, and with medical logistics providers both wholesale and distribution.How to participate?The opportunity will be available on the Atamis eTendering system, access here: https://atamis-1928.my.site.com/s/Welcome . If you do not already have an account you can easily register for one via the same link. You will then be able to search for this opportunity and access the questionnaire and any other related documents. Please note that all correspondence must be conducted through the Atamis system. The response window will close at 5pm on Friday 29th November 2024."
                        },
                        "where": {
                            "section": "II.2.4.1"
                        }
                    }
                ]
            },
            {
                "id": "2",
                "description": "The purpose of this notice is to provide an update regarding the Government's consideration of the Centralisation of Adult Flu Vaccine. We would like to express our gratitude for your ongoing interest and engagement in this matter.This project is characterised by significant complexity, and consequently, we are robustly exploring all available options to ensure efficient and successful delivery in alignment with the NHS Vaccination Strategy (2023), while also ensuring the engagement of all relevant stakeholders.Furthermore, to ensure market stability and to avoid any undue impact on the existing programme in the upcoming seasons, we can confirm that the proposed central procurement and distribution of Adult Flu Vaccine, which is subject to consultation with primary care representative bodies, will not aim to commence until Winter 2028 to 2029 at the earliest.We will ensure that sufficient notice is given for any proposed changes that are to be implemented.To note: This statement does not preclude the outcome of the consultation with the primary care representative bodies."
            },
            {
                "id": "3",
                "description": "The purpose of this notice is to provide an update regarding the Government's consideration of the Centralisation of Adult Flu Vaccine. We would like to express our gratitude for your ongoing interest and engagement in this matter. This project is characterised by significant complexity, and consequently, we are robustly exploring all available options to ensure efficient and successful delivery in alignment with the NHS Vaccination Strategy (2023), while also ensuring the engagement of all relevant stakeholders. Furthermore, to ensure market stability and to avoid any undue impact on the existing programme in the upcoming seasons, we can confirm that the proposed central procurement and distribution of Adult Flu Vaccine, which is subject to consultation with primary care representative bodies, will not aim to commence until Winter 2029 to 2030 at the earliest. We will ensure that sufficient notice is given for any proposed changes that are to be implemented. To note: This statement does not preclude the outcome of the consultation with the primary care representative bodies."
            }
        ]
    },
    "parties": [
        {
            "id": "GB-FTS-91907",
            "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency",
            "identifier": {
                "legalName": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency"
            },
            "address": {
                "streetAddress": "10 South Colonnade",
                "locality": "London",
                "region": "UKI42",
                "postalCode": "E14 4PU",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Major Programmes, UKHSA",
                "email": "industry@ukhsa.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/uk-health-security-agency",
                "buyerProfile": "https://www.gov.uk/government/organisations/uk-health-security-agency",
                "classifications": [
                    {
                        "id": "MINISTRY",
                        "scheme": "TED_CA_TYPE",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "id": "07",
                        "scheme": "COFOG",
                        "description": "Health"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-91907",
        "name": "Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency"
    },
    "language": "en"
}